Key Takeaways The U.S. Food and Drug Administration has delayed full approval of Novavax's COVID vaccineThe agency says it needs more data before making a final decisionNovavax says its vaccine is ...

Dr. Peter Marks is being forced to resign from the FDA because the Trump administration does not want someone who is ...

Peter Marks, the FDA’s top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary’s team sought ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

Shares of Nike (NYSE: NKE), the world's most popular shoe and apparel brand, dropped 15% earlier this week but have recovered ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

On the precipice of FDA approval, Novavax's Covid vaccine is now in limbo while a decision to approve or reject it is held up ...